- Oops!Something went wrong.Please try again later.
CD388 is a highly potent, long-acting antiviral immunotherapy designed to deliver universal prevention and treatment of seasonal and pandemic influenza, added the Company.
Cidara intends to initiate a Phase 1 study in healthy volunteers before the end of the current quarter.
In April 2021, Cidara announced an exclusive worldwide license and collaboration agreement with Janssen Pharmaceuticals Inc to develop and commercialize Cidara's Cloudbreak DFCs to prevent and treat seasonal and pandemic influenza.
Under the collaboration, Cidara is responsible for developing and manufacturing CD388 into the clinic and through Phase 2a clinical development.
Janssen is responsible for late-stage development, manufacturing, registration, and global commercialization.
Janssen will fund the Phase 1 trial-related development costs and future research, development, manufacturing, and commercialization for CD388.
Price Action: CDTX shares are down 0.12% at $0.80 during the market session on the last check Monday.
See more from Benzinga
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.